Is COVID-19 Friend or Foe to Industry 4.0: Experiences of Turkish White Goods Suppliers

被引:0
|
作者
Demirbag, Kubra Simsek [1 ]
Yildirim, Nihan [2 ]
机构
[1] Gumushane Univ, Management Informat Syst Dept, Gumushane, Turkey
[2] Istanbul Tech Univ, Management Engn Dept, Istanbul, Turkey
关键词
covid-19; fourth industrial revolution; industry; 4.0; pandemic; white goods;
D O I
10.1109/TEMSCONEUROPE54743.2022.9801958
中图分类号
T [工业技术];
学科分类号
08 ;
摘要
This study, in the two years since the beginning of the COVID-19 pandemic, reveals the most focused issues by the Turkish white goods suppliers regarding Industry 4.0 and the challenges encountered while engaging in Industry 4.0 practices. The data were obtained through a questionnaire form participated by the managers of 36 different companies that are members of the Turkish White Goods Suppliers Association. The collected data were classified, and it was found that the most focused issues of the companies were technology investments, ERP and MES, data collection, business processes, investment plans, organizational transformation, occupational health and safety, and participation in Industry 4.0-related events, respectively. Moreover, the most common challenges companies face concerning Industry 4.0 are related to the not being able to come together, finance, technology providers, postponement of investment plans, and loss of employees. On the other hand, 16% of the participating companies stated that they did not encounter any difficulties.
引用
收藏
页码:67 / 72
页数:6
相关论文
共 50 条
  • [41] Gastrointestinal symptoms in patients with coronavirus disease 2019 (COVID-19) - friend or foe?
    Lewandowski, Konrad
    Kaniewska, Magdalena
    Rosolowski, Mariusz
    Tworek, Adam
    Rydzewska, Grazyna
    GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY, 2022, 17 (03): : 219 - 226
  • [42] From Foe to Friend in COVID-19: Renin-Angiotensin System Inhibitors
    Kidde, Jason
    Sahebkar, Amirhossein
    JOURNAL OF INFECTIOUS DISEASES, 2021, 223 (01): : 174 - 175
  • [43] Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?
    Badagliacca, Roberto
    Sciomer, Susanna
    Petrosillo, Nicola
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (07): : 729 - 730
  • [44] SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?
    Scheen, A. J.
    DIABETES & METABOLISM, 2020, 46 (05) : 343 - 344
  • [45] Baricitinib as Treatment for Coronavirus Disease 2019 (COVID-19): Friend or Foe of the Pancreas?
    Cerda-Contreras, Christopher
    Nuzzolo-Shihadeh, Laura
    Camacho-Ortiz, Adrian
    Perez-Alba, Eduardo
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) : E3977 - E3978
  • [46] Nationwide practice on awake prone positioning for COVID-19 patients: 'a friend or foe?'
    Wilkinson, D.
    West, R.
    ANAESTHESIA, 2021, 76 : 92 - 92
  • [47] Ivermectin in the treatment of COVID-19-friend or foe?
    Schellack, N.
    Padayachee, N.
    Schellack, G.
    SA PHARMACEUTICAL JOURNAL, 2021, 88 (01) : 11 - +
  • [48] Renin-angiotensin system inhibition in COVID-19 patients: Friend or foe? Comment
    Karadag, Bilgehan
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2020, 24 (01): : 30 - 31
  • [49] FRIEND OR FOE? THE VIRTUAL WORLD AND COMMERCIAL SEXUAL EXPLOITATION OF CHILDREN IN THE ERA OF COVID-19
    Borlik, Marcy Forgey
    Greenbaum, Jordan
    Bath, Eraka
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2021, 60 (10): : S79 - S79
  • [50] Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe?
    Shylesh, Shakhi C. M.
    Arya, V. S.
    Kanthlal, S. K.
    Devi, Uma P.
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2022, 44 (01) : 1 - 10